ATTENTION CORT Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

Core Viewpoint - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant, which is intended to treat hypertension secondary to hypercortisolism [1][2]. Company Summary - On December 31, 2025, Corcept announced it received a Complete Response Letter (CRL) from the FDA, which denied the approval of relacorilant, citing the need for additional evidence of effectiveness despite acknowledging previous trial results [2]. - The stock price of Corcept fell by $31.42 (44.76%) to open at $38.78 per share on the same day, marking a new 52-week low and reaching levels not seen since September 2024 [3].